If achieving profit is a company’s goal, then having a healthy cash flow is essential to its existence, development and success. This is because cash offers strength, vitality and flexibility to make investment decisions as well as the fuel to run the growth engine.Investors flock to companies that earn profits but even a profitable business can succumb to failure if its cash flow is irregular and eventually files for bankruptcy. But a company’s resiliency can be fairly judged when its efficacy in generatin ...

Shares of Adma Biologics (ADMA) have gained 1.1% over the past four weeks to close the last trading session at $5.36, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $6.88 indicates a potential upside of 28.4%.The mean estimate comprises four short-term price targets with a standard deviation of $1.44. While the lowest estimate of $6 indicates an 11.9% increase from the current ...

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though?Let's take a look at what these Wall Street heavyweights have to say about Adma Biologics (ADMA) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.Adma Biologics currently ha ...

ADMA Biologics, Inc. (NASDAQ:ADMA) Q4 2023 Earnings Conference Call February 28, 2024 4:30 PM ET Company Participants Skyler Bloom - Senior Director, Business Development and Corporate Strategy Adam Grossman - President and CEO Brian Lenz - Executive Vice President, Chief Financial Officer and General Manager, ADMA BioCenters Conference Call Participants Anthony Petrone - Mizuho Kristen Kluska - Cantor Fitzgerald Gary Nachman - Raymond James Operator Good afternoon. And welcome to the ADMA Biologics Fourth ...

RAMSEY, N.J. and BOCA RATON, Fla., Feb. 28, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announced that Brian Lenz, Executive Vice President, Chief Financial Officer & General Manager, ADMA BioCenters will be transitioning from these positions to a consulting role, effective April 1, 2024. "On behalf of ADMA's Board of Directors and myse ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission File Number: 001-36728 ADMA BIOLOGICS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 56-2590442 (State or Other Jur ...

In the latest market close, Adma Biologics (ADMA) reached $5.18, with a +0.58% movement compared to the previous day. This change outpaced the S&P 500's 0.13% gain on the day. Elsewhere, the Dow gained 0.13%, while the tech-heavy Nasdaq lost 0.32%.Heading into today, shares of the infectious disease drug developer had lost 2.28% over the past month, lagging the Medical sector's gain of 3.87% and the S&P 500's gain of 2.99% in that time.The investment community will be paying close attention to the earnings ...

Adma Biologics (ADMA) closed the latest trading day at $5.40, indicating a +1.31% change from the previous session's end. The stock outperformed the S&P 500, which registered a daily gain of 0.58%. At the same time, the Dow added 0.91%, and the tech-heavy Nasdaq gained 0.3%.The infectious disease drug developer's shares have seen an increase of 8.11% over the last month, surpassing the Medical sector's gain of 2.39% and the S&P 500's gain of 4.61%.Market participants will be closely following the financial ...

While "the trend is your friend" when it comes to short-term investing or trading, timing entries into the trend is a key determinant of success. And increasing the odds of success by making sure the sustainability of a trend isn't easy.Often, the direction of a stock's price movement reverses quickly after taking a position in it, making investors incur a short-term capital loss. So, it's important to ensure that there are enough factors -- such as sound fundamentals, positive earnings estimate revisions, ...

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:Inhibikase Therapeutics, Inc. (IKT) : This pharmaceutical company has seen the Zacks Consensus Estimate for its current year earnings increasing 16% over the last 60 days.Equitrans Midstream Corporation (ETRN) : This midstream energy company has seen the Zacks Consensus Estimate for its current year earnings increasing 11.7% over the last 60 days.ADMA Biologics, Inc. (ADMA) : This biopharmaceutical company has seen the Zacks Consensus E ...